MedTrace Logo

First-in-Human Single and Multiple Dose of KLA578-1 for Injection

NCT07143318 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2026-05-15

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability and pharmacokinetics of single and multiple doses of KLA578-1 for injection in healthy volunteers

Conditions

  • Healthy Volunteers

Interventions

DRUG

KLA578-1 for injection

Intravenous injection, single dose

DRUG

Etopcoxib Tablets

P.O., single dose

Sponsors & Collaborators

  • Hunan Kelun Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-06-05
Primary Completion
2026-05-31
Completion
2026-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07143318 on ClinicalTrials.gov